MRM

MEDIROM Healthcare Technologies Inc. Consumer Cyclical - Personal Services Investor Relations →

YES
69.0% BELOW
↓ Approaching Was -68.7% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $3.74
14-Week RSI 46
Rel. Volume (14w) This week's trading vs. the 14-week average 0.1x — Quiet
Buyers vs. Sellers (14w) Are up-weeks or down-weeks getting more volume? 12.39 — Buyers winning

MEDIROM Healthcare Technologies Inc. (MRM) closed at $1.16 as of 2026-06-19, trading 69.0% below its 200-week moving average of $3.74. This places MRM in the extreme value zone. The stock is currently moving closer to the line, down from -68.7% last week. The 14-week RSI sits at 46, indicating neutral momentum.

Trading activity has gone quiet — just 0.1x of its usual 14-week average. But the buying that is happening outweighs the selling (12.39 buyers-vs-sellers ratio). When volume dries up but buyers are still showing up more than sellers, it can mean the worst of the selling is over and the stock is quietly building a floor.

Over the past 237 weeks of data, MRM has crossed below its 200-week moving average 1 time. On average, these episodes lasted 237 weeks.

With a market cap of $9 million, MRM is a small-cap stock. The company generates a free cash flow yield of 3409.6%, which is notably high. Return on equity stands at 53.2%, indicating strong profitability. The stock trades at 6.0x book value.

Share count has increased 61.8% over three years, indicating dilution.

Over the past 4.6 years, a hypothetical investment of $100 in MRM would have grown to $19, compared to $168 for the S&P 500. MRM has returned -30.3% annualized vs 11.9% for the index, underperforming the broader market over this period.

Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.

Business Health

Annual financials — how the underlying business has performed over the past several years.

Cash Flow Free cash flow & net income ($M)

Revenue Annual revenue ($M) — business growth proxy

Total Debt Balance sheet debt ($M)

ROIC Return on invested capital (%)

FCF Yield Free cash flow / market cap (%) — Yartseva signal

Gross Margin Pricing power & competitive moat (%)

Shares Outstanding Buybacks vs dilution (millions)

Growth of $100: MRM vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After MRM Crosses Below the Line?

Across 1 historical episodes, buying MRM when it crossed below its 200-week moving average produced an average return of -25.0% after 12 months (median -25.0%), compared to -18.0% for the S&P 500 over the same periods. After 24 months, the average return was -6.0% vs +3.0% for the index.

Each line shows $100 invested at the moment MRM crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Dislocation Scores Experimental

Each score measures deviation from MRM's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.

⚠ Earnings quality deteriorating — net income is outrunning free cash flow vs this company's own norm. Cheapness signals here deserve extra scrutiny.
Yield Dislocation N/A Dividend yield vs own 10-yr norm
Drawdown Score +1.16σ Distance from line vs own history
Sector-Relative N/A Vs sector median this week
Buyback Acceleration +44.4pp YoY share change vs own 3-yr pace (− = accelerating)
Insider Intensity N/A TTM buys / market cap, percentile of buyers
FCF Yield vs History +14259.3pp Vs own recent annual mean
Earnings Quality Deteriorating Accrual gap trend (+5.2pp of revenue)

Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.

Advertisement

Historical Touches

MRM has crossed below its 200-week MA 1 time

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Dec 2021Ongoing237+93.6%Ongoing-83.9%

Frequently Asked Questions

Is MRM below its 200-week moving average?

Yes. As of 2026-06-19, MEDIROM Healthcare Technologies Inc. (MRM) is trading 69.0% below its 200-week moving average of $3.74. The current price is $1.16.

What is MRM's 200-week moving average price?

MEDIROM Healthcare Technologies Inc.'s 200-week moving average is $3.74 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.

What happens when MRM drops below its 200-week moving average?

MRM has crossed below its 200-week moving average 1 time in our data. These episodes lasted 237 weeks on average.

Is MRM a good value right now?

Here's what our data says about MRM as of 2026-06-19: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 46. Free cash flow yield is 3409.6%. Return on equity is 53.2%. Price-to-book is 6.0x. This is not a buy or sell recommendation — always do your own research.

How does MRM compare to the S&P 500?

Over the past 4.6 years, $100 invested in MRM would have grown to $19, compared to $168 for the S&P 500. That's -30.3% annualized vs 11.9% for the index. MRM has underperformed the broader market over this period.

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of week of 2026-06-19